[Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens].
Fifty eight patients with rhino-conjunctivitis caused by grass pollen were included in a double-blind study in which they received, by the sub-lingual route over 5 months, either a solution of purified and standardised allergen or a placebo. Assessment of the effect of this immunotherapy, which was done with drops of Stallergenes "5-grass pollen" was by clinical symptoms and the use of authorized drugs and treatments. Compared with the placebo group, the patients on active treatment showed significantly less (P = 0.05 to P = 0.01) rhinitis symptoms (sneezing and rhinorrhea) and conjunctivitis (reddening and tears) during the pollen season. Consumption of nasal cromoglycate solution, of betamethasone and dexchlorpheniramine was significantly lower (p = 0.01) in the desensitised group. Secondary effects were negligible. From this study, it can be concluded that immunotherapy with grass pollen extract, by the sub-lingual route, of patients with rhino-conjunctivitis who were sensitive to these allergens, is efficacious, easy to do, economic and sure.
Sabbah
A
A
Laboratoire d'Immuno-Allergologie, C.H.U.F., Angers.
Lesellin
J
J
Hassoun
S
S
Sicard
H
H
André
C
C
D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D001623:Betamethasone / Q000627:therapeutic use; D002744:Chlorpheniramine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003233:Conjunctivitis, Allergic / Q000188:drug therapy / Q000628:therapy*; D004205:Cromolyn Sodium / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006109:Poaceae; D011058:Pollen / Q000276:immunology*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000628:therapy*; D016593:Terfenadine / Q000627:therapeutic use; D016896:Treatment Outcome
D000485:Allergens; C018904:dexchlorpheniramine; D002744:Chlorpheniramine; D016593:Terfenadine; D001623:Betamethasone; D004205:Cromolyn Sodium
Immunothérapie spécifique par voie sublinguale de la rhinoconjonctivite aux pollens de graminées.